SOHM, Inc. Continues to Build its IP Portfolio in the Gene Editing and Cell Engineering Space
Rhea-AI Summary
SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company, has filed a new provisional patent application with the USPTO. The application, titled 'DONOR NUCLEIC ACIDS FOR RNA GUIDED INTEGRASES AND MULTIPLEX GUIDE RNA SYSTEM FOR TARGETING', describes specific combinations of guide RNAs used with the ABBIE system to increase targeting and efficiency.
This development comes ten months after SOHM's announcement of their 'SMART' gene editing provisional application. The company aims to expand its patent portfolio in the cell engineering space, with the goal of becoming a significant player and leader in gene editing technology and products.
Dr. David Aguilar, COO of SOHM, expressed satisfaction with the progress in developing the ABBIE system and its potential, stating that these technical advances provide the competitive edge needed in this highly contested field.
Positive
- Filed new provisional patent application for RNA guided integrases and multiplex guide RNA system
- Expanding patent portfolio in cell engineering and gene editing space
- Continued development of ABBIE system for increased targeting and efficiency
Negative
- None.
News Market Reaction
On the day this news was published, SHMN declined NaN%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
CHINO HILLS, CA / ACCESSWIRE / October 2, 2024 / SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology company specializing in generic drugs, has announced today that the company has filed new provisional patent application with USPTO.
Dr. David Aguilar, COO, SOHM, Inc. announced that the company has filed a new provisional application entitled;
"DONOR NUCLEIC ACIDS FOR RNA GUIDED INTEGRASES AND MULTIPLEX GUIDE RNA SYSTEM FOR TARGETING"
Dr. Aguilar further added that the application describes specific combinations of guide RNAs used with the ABBIE system for increased targeting and efficiency of the ABBIE system. SOHM continues to grow its patent portfolio in the cell engineering space with the intention of becoming a significant player and leader in technology and products for gene editing. This announcement comes just ten months after the announcement of their "SMART" gene editing provisional application leveraging graphene material science with gene editing and cell engineering applications.
We are very happy with our progress in developing our ABBIE system and expanding it's potential. The continued technical advances allow our team to gain the competitive edge needed to be successful in this highly contested space said Dr. David Aguilar COO
About SOHM, Inc.:
SOHM is a biopharmaceutical company dedicated to developing and commercializing gene editing technologies for research, synthetic biology, and therapeutic applications. With a focus on precision medicine, SOHM aims to revolutionize the treatment of genetic diseases by providing safe, efficient, and targeted gene editing solutions. Through strategic collaborations and groundbreaking research, SOHM is at the forefront of advancing the field of gene therapy.
To learn more about SOHM, Inc., visit www.SOHM.com.
SOHM, Inc.:
Name: Baron Night, CEO/Dr. David Aguilar, COO
Email: info@sohm.com
Phone: (714) 522-6700
Safe Harbor Statement:
This news release contains "forward-looking statements," which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development-stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report for the most recent fiscal year and our quarterly reports uploaded from time to time on OTCMarkets.com.
SOURCE: SOHM, Inc
View the original press release on accesswire.com
FAQ
What new patent application has SOHM Inc (SHMN) filed with the USPTO?
How does the new patent application relate to SOHM's (SHMN) ABBIE system?
What is SOHM Inc's (SHMN) goal in the gene editing and cell engineering space?
When did SOHM Inc (SHMN) announce their 'SMART' gene editing provisional application?
